[1] |
Rebbeck T R.Genetics, disparities, and prostate cancer[J]. LDI Issue Brief 2005, 10(7): 1~4.
|
[2] |
Landis S H, Murray T, Bolden S, et al. Cancer statistics[J]. Cancer J Clin, 1998, 48(6~29): 43~62.
|
[3] |
Nakazato T, Ito K, Miyakawa Y, et al. Catechin, a green tea component, rapidly induces apoptosis of myeloid leukemic cells via modulation of reactive oxygen species production in vitro and inhibits tumor growth in vivo[J]. Haematologica, 2005, 90(3): 317~325.
|
[4] |
Kinlen, L J, Willows A N, Goldblatt P, et al. Tea consumption and cancer[J]. Brit J Cancer, 1988(58): 397~401.
|
[5] |
Heilburn L K, Nomura A, Stemmermann, G N.Black teaconsumption and cancer risk: A prospective study[J]. Br J Cancer, 1986(54): 677~683.
|
[6] |
Wynder E L, Rose D P, Cohen L A.Nutrition and prostate cancer: a proposal for dietary intervention[J]. Nutr Cancer, 1994(22): 1~10.
|
[7] |
Hussain T, Gupta S, Adhami V M, et al. Green tea constituent epigallocatechin-3-gallate selectively inhibits COX-2 without affecting COX-1 expression in human prostate carcinoma cells[J]. Int J Cancer, 2005, 113(4): 660~669.
|
[8] |
Hiipakka R A., Zhang H Z, Dai W, et al. Structure-activity relationships for inhibition of human 5alpha-reductases by polyphenols[J]. Biochem Pharmacol, 2002, 63(6): 1165~1176.
|
[9] |
Brusselmans K, De Schrijver E, Heyns W, et al. Epigallocatechin-3-gallate is a potent natural inhibitor of fatty acid synthase in intact cells and selectively induces apoptosis in prostate cancer cells[J]. Int J Cancer, 2003, 106(6): 856~862.
|
[10] |
Pezzato E., Sartor L, Dell'Aica I, et al. Prostate carcinoma and green tea: PSA-triggered basement membrane degradation and MMP-2 activation are inhibited by (-) epigallocatechin-3-gallate[J]. Int J Cancer, 2004, 112(5): 787-792.
|
[11] |
Vayalil P K, Katiyar S K.Treatment of epigallocatechin-3-gallate inhibits matrix metalloproteinases-2 and -9 via inhibition of activation of mitogen-activated protein kinases, c-jun and NF-kappaB in human prostate carcinoma DU-145 cells[J]. Prostate 2004, 59(1): 33~42.
|
[12] |
Ren F, Zhang S, Mitchell, S H, et al. Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells[J]. Oncogene, 2000, 19(15): 1924~32.
|
[13] |
Ishii,K., Otsuka T., Iguchi K., et al. Evidence that the prostate-specific antigen (PSA)/Zn2+ axis may play a role in human prostate cancer cell invasion[J]. Cancer Lett,2004, 207(1):79~87.
|
[14] |
Scudiero D A, Shoemarker R H, Paull K D, et al. Evaluation of a soluble tetrazolium/formaza assay for cell growth and drug sensitivity in culture using human and other tumor cell lines[J]. Cancer Res, 1998(48): 4827.
|
[15] |
Ayhan D, Erol P, Fethiye G, et al. Adsorption of Cu(Ⅱ), Zn, 2005(282): 20~25.
|
[16] |
Liang Y R.Analysis of theaflavins by HPLC-photodiode arraydetector. Acta[J]. Agriculture.Universitati 1992, 18(s): 70~74.
|
[17] |
Tang D S, Shen S R, Chen X., et al. Interaction of catechins with aluminum in vitro[J]. J Zhejiang Univ Sci 2004, 5(6): 668~675.
|
[18] |
K Midori, S Tamiyoshi, Kinuyo, et al. Effects of pH and metal ions on antioxidative activities of catechins[J]. Biosci Biotechnol Biochem, 2000(65): 126~132.
|
[19] |
Ogumlewa J O, Osegbe D N.Zinc and cadmium concentrations in indigenous blacks with normal, hypertrophic and malignante prostate[J]. Cancer, 1989(63): 1388~1392.
|
[20] |
Satoh M, Koyama H, Kaji T, et al. Perspectives on cadmium toxicity research[J]. Tohoku J Exp Med 2002, 196(1): 23~32.
|
[21] |
Reed M J.The uptake of testosterone and Zinc in vitro by the human hypertrophic prostate[J]. J Endo, 1973(58): 405.
|